Skip to main navigation Skip to search Skip to main content

de la Vega, Laureano

Dr

20032025

Research activity per year

Personal profile

Biography

Laureano de la Vega is a biochemist graduate from the University of Cordoba (Spain), he finished his PhD in Biochemistry in 2007 obtaining the highest degree, Summa Cum Laude, for his work investigating the molecular mechanisms regulating HIV latency. Following this, he moved to Giessen (Germany) to join the team of Prof. Lienhard Schmitz as a postdoctoral researcher from 2007 to 2013. During that time his research was focused on post-translational modifications of HIPK2, an important regulator of cell growth, cell death and differentiation. In 2013 he moved to Dundee where he started his own group focused on the regulation of stress response pathways in cancer.

 

Research interests

Stress Responses

Organisms need to be able to adapt to change in order to survive, and certain cellular programs (stress response pathways) have evolved to respond to a dynamic environment. Example of stress responses pathways include p53, NRF2, and HSF1 pathways. Stress responses are by definition acute, and their transient activation help normal cells to cope with cellular stresses. Interestingly, there is a large body of evidence showing that, in contrast to normal cells, cancer cells are constitutively under cellular stress (i.e. DNA damage/replication stress, proteotoxic stress, mitotic stress, metabolic stress, and oxidative stress) and they depend on the sustained activation of cytoprotective stress response pathways to survive.

The essential nature of the stress response pathways in cancer cells makes them attractive targets, and thus, a better understanding of how these pathways are regulated could help identify new ways to modulate stress responses to impair cancer cell survival. In that sense, our lab is focused in obtaining a detailed understanding of stress response pathways and their aberrations in cancer. For that, we are interested not only on key master regulators of stress responses (e.g. NRF2, HSF1 or P53) but as well in the upstream regulatory pathways that modulate their activity (i.e. upstream kinases).

Teaching

Laureano is the Science and Health Communication MSc Programme Lead, where he is also module manager for three modules; he also leads the level 4 Cancer Pharmacology and Treatment module within the Biomedical and Biological sciences courses.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics where Laureano de la Vega is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
  • Identification of a BACH1 lung cancer signature: A novel tool for understanding BACH1 biology and identifying new inhibitors

    Klenja Skudrinja, D., Ali, K. X., Walker, D., Higgins, M., Patel, A. A., Raj, D., Creelman, A., McDowall, C., Taylor, C., Wenta, T., Larsson, E., Wiel, C., Sayin, V. I. (Lead / Corresponding author) & de la Vega, L. (Lead / Corresponding author), Sept 2025, In: Redox Biology. 85, 103789.

    Research output: Contribution to journalArticlepeer-review

    Open Access
    File
    95 Downloads (Pure)
  • Identification of a BACH1 lung cancer signature: A novel tool for understanding BACH1 biology and identifying new inhibitors

    Klenja Skudrinja, D., Walker, D., Ali, K. X., Higgins, M., Patel, A. A., Raj, D., Creelman, A., McDowall, C., Wenta, T., Larsson, E., Wiel, C., Sayin, V. I. (Lead / Corresponding author) & de la Vega, L. (Lead / Corresponding author), 13 Jan 2025, BioRxiv, 41 p.

    Research output: Working paper/PreprintPreprint

  • Author Correction: Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways

    Kurmasheva, N., Said, A., Wong, B., Kinderman, P., Han, X., Rahimic, A. H. F., Kress, A., Carter-Timofte, M. E., Holm, E., van der Horst, D., Kollmann, C. F., Liu, Z., Wang, C., Hoang, H.-D., Kovalenko, E., Chrysopoulou, M., Twayana, K. S., Ottosen, R. N., Svenningsen, E. B. & Begnini, F. & 31 others, Kiib, A. E., Kromm, F. E. H., Weiss, H. J., Di Carlo, D., Muscolini, M., Higgins, M., van der Heijden, M., Arulanandam, R., Bardoul, A., Tong, T., Ozsvar, A., Hou, W.-H., Schack, V. R., Holm, C. K., Zheng, Y., Ruzek, M., Kalucka, J., de la Vega, L., Elgaher, W. A. M., Korshoej, A. R., Lin, R., Hiscott, J., Poulsen, T. B., O'Neill, L. A., Roy, D. G., Rinschen, M. M., van Montfoort, N., Diallo, J.-S., Farin, H. F., Alain, T. & Olagnier, D. (Lead / Corresponding author), 19 Dec 2024, In: Nature Communications. 15, 1 p., 10698.

    Research output: Contribution to journalArticlepeer-review

    Open Access
    File
    30 Downloads (Pure)
  • Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways

    Kurmasheva, N., Said, A., Wong, B., Kinderman, P., Han, X., Rahimic, A. H. F., Kress, A., Carter-Timofte, M. E., Holm, E., van der Horst, D., Kollmann, C. F., Liu, Z., Wang, C., Hoang, H.-D., Kovalenko, E., Chrysopoulou, M., Twayana, K. S., Ottosen, R. N., Svenningsen, E. B. & Begnini, F. & 31 others, Kiib, A. E., Kromm, F. E. H., Weiss, H. J., Di Carlo, D., Muscolini, M., Higgins, M., van der Heijden, M., Arulanandam, R., Bardoul, A., Tong, T., Ozsvar, A., Hou, W.-H., Schack, V. R., Holm, C. K., Zheng, Y., Ruzek, M., Kalucka, J., de la Vega, L., Elgaher, W. A. M., Korshoej, A. R., Lin, R., Hiscott, J., Poulsen, T. B., O'Neill, L. A., Roy, D. G., Rinschen, M. M., van Montfoort, N., Diallo, J.-S., Farin, H. F., Alain, T. & Olagnier, D. (Lead / Corresponding author), 15 May 2024, In: Nature Communications. 15, 1, 28 p., 4096.

    Research output: Contribution to journalArticlepeer-review

    Open Access
    File
    190 Downloads (Pure)
  • Dual inhibition of HSF1 and DYRK2 impedes cancer progression

    Tandon, V., Moreno, R., Allmeroth, K., Quinn, J., Wiley, S. E., Nicely, L. G., Denzel, M. S., Edwards, J., de la Vega, L. & Banerjee, S. (Lead / Corresponding author), Jan 2023, In: Bioscience Reports. 43, 1, 14 p., BSR20222102.

    Research output: Contribution to journalArticlepeer-review

    Open Access
    File
    170 Downloads (Pure)